Antigen-specific immunity and risk of progression to clinical myeloma. (A) SOX2-specific T cells and risk of progression to clinical myeloma requiring therapy. (B) Virus (CEF)–specific T cells and risk of progression to clinical myeloma requiring therapy. (C) Detection of EBNA1-specific antibodies and risk of progression to clinical myeloma requiring therapy. (D) Detection of tetanus-specific antibodies and risk of progression to clinical myeloma requiring therapy. (E) Reduction in clonally uninvolved immunoglobulins and risk of progression to clinical myeloma requiring therapy.